Table 3:
Changes in serum levels of iPTH and cCa stratified according to the administration of VDRAs and dialysate calcium concentration.
| Baseline | Week 18 | Week 52 | |
|---|---|---|---|
| Baseline VDRAs use | |||
| User of VDRAs | |||
| Number | 46 | 45 | 41 |
| Serum iPTH (pg/mL) | 322 (253, 536) | 199 (142, 280) | 137 (101, 201) |
| Serum cCa (mg/dL) | 9.68 ± 0.64 | 8.61 ± 0.60 | 9.25 ± 0.82 |
| Nonuser of VDRAs | |||
| Number | 12 | 11 | 11 |
| Serum iPTH (pg/mL) | 324 (288.5, 400) | 190 (145, 395) | 144 (72, 202) |
| Serum cCa (mg/dL) | 9.08 ± 0.64 | 8.30 ± 0.17 | 8.65 ± 0.55 |
| Baseline dialysate calcium concentration | |||
| 1.25 mmol/L [2.5 mEq/L] | |||
| Number | 12 | 11 | 11 |
| Serum iPTH (pg/mL) | 321.5 (278.5, 521.5) | 262 (132, 371) | 137 (62, 203) |
| Serum cCa (mg/dL) | 9.34 ± 0.72 | 8.19 ± 0.42 | 9.25 ± 1.14 |
| 1.375 mmol/L [2.75 mEq/L] | |||
| Number | 16 | 15 | 15 |
| Serum iPTH (pg/mL) | 276.5 (214.5, 310.5) | 188 (99, 311) | 131 (80, 229) |
| Serum cCa (mg/dL) | 9.28 ± 0.62 | 8.53 ± 0.67 | 8.82 ± 0.64 |
| 1.5 mmol/L [3.0 mEq/L] | |||
| Number | 30 | 30 | 26 |
| Serum iPTH (pg/mL) | 442.5 (301, 591) | 181.5 (150, 263) | 156 (94, 191) |
| Serum cCa (mg/dL) | 9.80 ± 0.64 | 8.69 ± 0.49 | 9.25 ± 0.70 |
Data are presented as median (25th percentile, 75th percentile) or mean ± standard deviation.
cCa, corrected calcium; iPTH, intact parathyroid hormone; VDRA, vitamin D receptor activator.